1.Diagnosis and treatment of primary angitis of central nervous system.
Mingguang ZHANG ; Qiwu XU ; Xiaoming JU ; An SUN ; Weimin BAO ; Fulin ZHANG
Chinese Journal of Nervous and Mental Diseases 2001;27(1):35-37
Objective To investigate methods for the diagnosis and treatment of primary angitis of central nervous system (PACNS). Methods Radiological and clinical feature, operative resutls of 12 patients with mass lesion presentations of PACNS were analyzed retrospectively. Results The lesions showed low density on CT and long T1 and long T2 signal on MRI. The ring-wall enhanced lesions on MRI were flowery in 7 patients. Gross total resection of the lesions were performed in 10 patients with excellent recovery postoperatively. Growth of lesions were observed in 2 patients who underwent subtotal resection. Conclusions Lesions of PACNS have special appearance on enhanced MRI. More patients with mass lesion presentations of PACNS could be diagnosed preoperatively according to radiological and clinical feature.For these patients, surgery is the optimal treatment at present.
2.Pharmaceutical Care for One Patient with Ⅳ Degree Myelosuppression Treated with the Combination of Chinese and Western Medicines
Bei HUANG ; Xiaojian XIA ; Qiwu SUN ; Qingping SHI ; Minghong BI ; Muhua WANG
China Pharmacist 2017;20(8):1408-1411
Objective: To investigate the breakthrough points and methods of pharmaceutical care performed by clinical pharmacists for chemotherapy-induced Ⅳ degree myelosuppression.Methods: One advanced lung adenocarcinoma patient suffering from chemotherapy-induced Ⅳ degree myolosuppression was selected as the example, clinical pharmacists provided suggestions on the chemotherapy regimen, assisted physicians in making reasonable treatment plan and implemented comprehensive pharmaceutical care for the patient.Results: Clinical pharmacists played a positive role in the clinical treatment through the comprehensive pharmaceutical care in oncology department.Conclusion: With the professional knowledge of pharmacy, clinical pharmacists can improve the level of clinical rational drug use.
3.Expression of serum miR-638 in breast cancer and its clinical value
Linhai LI ; Bin XIAO ; Xi CHEN ; Zhaohui SUN ; Zhenzhan KUANG ; Qiwu WEN
Chinese Journal of Clinical Laboratory Science 2019;37(12):901-904
Objective:
To investigate the expression levels of serum miR-638 in the patients with breast cancer and its clinical value.
Methods:
One hundred and fifty-two patients with breast cancer were selected as the disease group, and 102 healthy persons as the control group. The expression levels of miR-638 in their serum samples were detected by the quantitative reverse transcription-polymerase chain reaction (qRT-PCR), and the expression levels of serum miR-638 in the patients with different pathological stages, before and after operation, and before and after chemotherapy were compared. The diagnosis efficacy of serum miR-638 alone and in combination with CEA, CA125, CA15-3 for breast cancer was analyzed by the ROC curve and Z test.
Results:
The expression levels of serum miR-638 in the breast cancer group (3.6 [1.3~10.5]) were significantly lower than that in the control group (79.0 [52.5~120.8],P<0.01). The linear regression analysis showed that chemotherapy and pathological staging were the main factors influencing the expression levels of serum miR-638. The area under the ROC curve (AUC ROC ) of serum miR-638 in the diagnosis of breast cancer was 0.954. When the cut-off value of serum miR-638 was 27.47, its sensitivity and specificity for the diagnosis of breast cancer were 94% and 86.2%, respectively. The area under the ROC curve (AUC ROC ) of serum miR-638 combined with CEA, CA125 and CA15-3 in the diagnosis of breast cancer was 0.978 8. When the combined cut-off value was 0.29, their sensitivity and specificity for the diagnosis of breast cancer were 95.4% and 89.5%, respectively. There was no significant difference in the AUC ROC between miR-638 alone and combined screening (Z=1.68,P=0.091).
Conclusion
Serum miR-638 may be a potential molecular marker for the screening of breast cancer.
4.Reliability and validity of the Chinese version of the Social Connectedness Scale
Caizhi WU ; Ting WANG ; Wenting DUAN ; Weixin WANG ; Qiwu SUN
Journal of Xi'an Jiaotong University(Medical Sciences) 2022;43(4):496-502
【Objective】 To revise the Social Connectedness Scale-Revised (SCS-R) so as to explore the factor structure of SCS-R in the context of Chinese culture and test its reliability and validity. 【Methods】 Totally 900 college students were asked to complete the Chinese version of the Social Connectedness, and 850 valid questionnaires were collected. In addition, the Distress Disclosure scale (DDI) and UCLA Loneliness Scale were used as the criteria. One month later, 100 students were randomly selected for retest. 【Results】 ① The results of exploratory factor analysis showed that one factor with more than one eigenvalue was selected, and the cumulative variance explained was 62.44%. ② Confirmatory factor analysis showed that the data fit well (χ2=33.438, df=14, χ2/df=2.388, RMSEA=0.04, CFI=0.996, TLI=0.991). ③ The Chinese version of the social connectedness scale is a one-dimensional scale. Its internal consistency coefficient is 0.916 and test-retest reliability is 0.845. ④ Social connectedness is significantly positively correlated with distress disclosure and negatively correlated with loneliness, indicating that the scale has good criterion-related validity. 【Conclusion】 The Chinese version of the social connectedness scale has satisfactory reliability and validity, and has cross-cultural adaptability.